Compare CCHH & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CCHH | KALA |
|---|---|---|
| Founded | 2015 | 2009 |
| Country | Malaysia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.3M | 16.1M |
| IPO Year | 2025 | 2017 |
| Metric | CCHH | KALA |
|---|---|---|
| Price | $0.77 | $0.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | ★ 20.8M | 941.6K |
| Earning Date | 02-27-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.01 | N/A |
| Revenue | ★ $9,138,264.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.36 | $0.35 |
| 52 Week High | $15.39 | $20.60 |
| Indicator | CCHH | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 44.34 | 35.36 |
| Support Level | $0.36 | $0.40 |
| Resistance Level | $1.79 | $0.46 |
| Average True Range (ATR) | 0.22 | 0.05 |
| MACD | 0.19 | -0.00 |
| Stochastic Oscillator | 30.77 | 20.40 |
CCH Holdings Ltd operates a hotpot restaurant chain in Malaysia, specializing in chicken hotpot and fish head hotpot, mainly under two brand, namely Chicken Claypot House and Zi Wei Yuan, owned by the wholly owned subsidiaries of the Company. The Company conducts its operations through its wholly owned subsidiaries in Malaysia and is engaged as a restaurant operator, licensor and loyalty owner, and general trader. Currently, the Group has developed a restaurant chain including approximately 15 company-owned restaurant outlets, 13 franchised restaurant outlets in Malaysia, and 4 franchised restaurant outlets outside Malaysia.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.